Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings Inc (NASDAQ: LIXT) maintains this comprehensive news hub for investors tracking developments in its clinical-stage cancer therapeutics. Our curated collection features official press releases, regulatory filings, and material event announcements related to the company’s protein phosphatase inhibitor pipeline.
This resource enables stakeholders to monitor critical updates including clinical trial progress for lead compound LB-100, financial disclosures, and strategic collaborations. All content is sourced directly from company communications and SEC filings to ensure reliability.
Key categories include Phase 1/2 trial results, intellectual property milestones, executive leadership changes, and quarterly earnings reports. Bookmark this page for timely access to investment-relevant developments in Lixte’s novel approach to enhancing chemotherapy and radiation efficacy through targeted phosphatase inhibition.
LIXTE Biotechnology Holdings has initiated its first clinical trial in Spain to evaluate the effectiveness of LB-100 in enhancing the cytotoxic effects of chemotherapy for patients with advanced soft tissue sarcoma (ASTS). Conducted by the Spanish Sarcoma Research Group (GEIS), the trial will commence at Fundación Jiménez Díaz University Hospital in Madrid, with additional sites planned in Valencia and Barcelona.
The Phase 1b trial aims to identify the recommended phase 2 dose and will involve approximately 150 patients randomized to receive either doxorubicin alone or in combination with LB-100. Completion is expected within nine months, paving the way for a subsequent Phase 3 trial.
CEO John S. Kovach expressed optimism about assessing LB-100's potential in improving treatment outcomes for ASTS, emphasizing the critical need for effective therapies.
LIXTE Biotechnology Holdings announced a significant step in its Phase 1b clinical trial for LB-100, a first-in-class protein phosphatase 2A inhibitor, to enhance treatment for extensive stage small cell lung cancer (ED-SCLC).
The Sarah Cannon Research Institute (SCRI) at Tennessee Oncology will now participate in the trial, led by notable oncologists.
John S. Kovach, M.D., emphasized that SCRI's involvement will accelerate patient recruitment, potentially demonstrating LB-100's efficacy in improving treatment outcomes for this aggressive cancer.
LIXTE Biotechnology Holdings has reported new insights on its lead clinical compound, LB-100, demonstrating that deficiency in PP2A can enhance the efficacy of immune checkpoint blockers in cancer treatment. An article published in The Journal of Clinical Investigation outlines a previously unappreciated mechanism linking PP2A to immunosuppression in tumors. CEO John S. Kovach highlighted the potential of LB-100 in immunotherapy, particularly for extensive stage small cell lung cancer, where a clinical trial is currently recruiting participants. This study aims to evaluate LB-100's effectiveness in conjunction with chemotherapy and immune blockers.
LIXTE Biotechnology Holdings announced promising results from preclinical studies using its lead clinical compound LB-100, in combination with a WEE1 kinase inhibitor, showing remarkable effectiveness in killing cancer cells, particularly in tough cases like colorectal, pancreatic, and bile duct carcinomas.
Notably, when cancer cells developed resistance to this therapy, they lost their cancerous properties in animal models. This indicates a novel concept termed “tumor suppressive drug resistance”, suggesting that the resistance can lead to decreased oncogenic capacity. The findings present a potential breakthrough in cancer treatment, emphasizing the unique mechanism of LB-100.
LIXTE Biotechnology Holdings (Nasdaq:LIXT) will present at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference on December 7, 2022, at 3:30 p.m. EST. John S. Kovach, M.D., founder and CEO, will lead the presentation and host a Q&A session.
The conference showcases LIXTE's lead compound, LB-100, a novel protein phosphatase inhibitor with potential in cancer therapy. Interested attendees can access the presentation via this webcast link.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) has gained authorization from the Spanish Agency for Medicines (AEMPS) for a Phase 1b/randomized Phase 2 study of LB-100, its lead compound, combined with doxorubicin for treating advanced soft tissue sarcomas (ASTS). This study aims to determine the efficacy and safety of the combination versus doxorubicin alone, which has been the standard treatment for over 40 years. With up to 170 patients expected, results may enhance treatment outcomes in this niche area, potentially changing existing protocols.
